Profession

Scientists tell how to streamline drug research

Sharing data early on tops researchers' priority list for speeding up new drug discoveries.

By Myrle Croasdale — Posted Sept. 26, 2005

Print  |   Email  |   Respond  |   Reprints  |   Like Facebook  |   Share Twitter  |   Tweet Linkedin

The current model of drug development is inefficient, redundant and costly, according to a report by the Assn. of American Medical Colleges and the federal Food and Drug Administration.

The topic is such a hot one that research groups and think tanks have requested at least 4,000 copies of the August report that was the result of a January conference where researchers gathered to talk about how to rid drug research of the secrecy that's hindering new developments.

David Korn, MD, senior vice president of the AAMC's division of biomedical and health sciences research hopes that the large number of requests is a sign that drug companies, universities and government groups are prepared to make the fundamental changes outlined in the report.

"The current drug development methodology yields a very small return for an awful amount of work," Dr. Korn said. He cited data from Pfizer estimating that it takes 15 years and $881 million to screen 11 million compounds to get one new drug approved by the FDA.

Dr. Korn said researchers were eager to eliminate repeating each others' mistakes, but the framework to do that requires a fundamental change in an industry that keeps data secret and restricts sharing information with intellectual property claims.

To begin to ease restrictions, researchers recommended creating collaborative systems to share research, such as toxicology data, which is considered "pre-competitive," or part of the building blocks of development far from the final product stage.

With such data, Dr. Korn said researchers would be able to recognize early signs of organ toxicity, keeping them from wasting time and money pursuing dead ends.

They also recommended that the industry develop mechanisms to facilitate learning from failures, such as a consortium to analyze failed clinical trials.

In addition, researchers favored designing new regulatory incentive policies for small-market drugs and creating agreements that allowed them to share information now restricted as intellectual property or proprietary.

"Everyone agrees we need a better system that's quicker and much less expensive," Dr. Korn said. "If we could succeed in starting this process, it would be a wonderful achievement. The first step is always very difficult, but it's not rocket science."

Back to top


RELATED CONTENT

ADVERTISEMENT

ADVERTISE HERE


Featured
Read story

Confronting bias against obese patients

Medical educators are starting to raise awareness about how weight-related stigma can impair patient-physician communication and the treatment of obesity. Read story


Read story

Goodbye

American Medical News is ceasing publication after 55 years of serving physicians by keeping them informed of their rapidly changing profession. Read story


Read story

Policing medical practice employees after work

Doctors can try to regulate staff actions outside the office, but they must watch what they try to stamp out and how they do it. Read story


Read story

Diabetes prevention: Set on a course for lifestyle change

The YMCA's evidence-based program is helping prediabetic patients eat right, get active and lose weight. Read story


Read story

Medicaid's muddled preventive care picture

The health system reform law promises no-cost coverage of a lengthy list of screenings and other prevention services, but some beneficiaries still might miss out. Read story


Read story

How to get tax breaks for your medical practice

Federal, state and local governments offer doctors incentives because practices are recognized as economic engines. But physicians must know how and where to find them. Read story


Read story

Advance pay ACOs: A down payment on Medicare's future

Accountable care organizations that pay doctors up-front bring practice improvements, but it's unclear yet if program actuaries will see a return on investment. Read story


Read story

Physician liability: Your team, your legal risk

When health care team members drop the ball, it's often doctors who end up in court. How can physicians improve such care and avoid risks? Read story

  • Stay informed
  • Twitter
  • Facebook
  • RSS
  • LinkedIn